- Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDT
- The abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm ET
SOUTH
SAN FRANCISCO, Calif., April 24,
2024 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(Nasdaq: IDYA), a precision medicine oncology company committed to
the discovery and development of targeted therapeutics, today
announced that interim results from the investigator-sponsored
Phase 2 trial evaluating darovasertib safety and efficacy as
neoadjuvant/adjuvant treatment in uveal melanoma (UM) have been
selected for an oral presentation at the 2024 American Society of
Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois.
Details for the oral presentation are as follows:
Session: Melanoma/ Skin Cancers
Title: A Phase 2 Safety and Efficacy Study of
Neoadjuvant/Adjuvant Darovasertib for Localized Ocular Melanoma
Presenter: Anthony
Joshua, M.B.B.S, Ph.D., FRACP
Abstract number: 9510
Date and Time: June 3,
2024, at 9:51 AM CDT
ASCO will publish the abstract summary on Thursday, May 23, 2024, at approximately
5:00 pm ET.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the
discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's approach
integrates capabilities in identifying and validating translational
biomarkers with drug discovery to select patient populations most
likely to benefit from its targeted therapies. IDEAYA is applying
its research and drug discovery capabilities to synthetic lethality
– which represents an emerging class of precision medicine
targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to the timing and
content of future press releases. Such forward-looking statements
involve substantial risks and uncertainties that could cause
IDEAYA's preclinical and clinical development programs, future
results, performance or achievements to differ significantly from
those expressed or implied by the forward-looking statements. Such
risks and uncertainties include, among others, the uncertainties
inherent in the drug development process, including IDEAYA's
programs' early stage of development, the process of designing and
conducting preclinical and clinical trials, the regulatory approval
processes, the timing of regulatory filings, the challenges
associated with manufacturing drug products, IDEAYA's ability to
successfully establish, protect and defend its intellectual
property, the effects on IDEAYA's business of the worldwide
COVID-19 pandemic, the ongoing military conflict between
Russia and Ukraine, banking sector volatility, and other
matters that could affect the sufficiency of existing cash to fund
operations. IDEAYA undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties that could cause actual results to differ from
those expressed in these forward-looking statements, as well as
risks relating to the business of IDEAYA in general, see IDEAYA's
Annual Report on Form 10-K dated February
20, 2024 and any current and periodic reports filed with the
U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-asco-2024-oral-presentation-for-darovasertib-in-neoadjuvant-uveal-melanoma-phase-2-investigator-sponsored-study-302125242.html
SOURCE IDEAYA Biosciences, Inc.
